PRCT PE Ratio & Valuation,Is PRCT Overvalued

PRCT Relative Valuation

PRCT's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, PRCT is overvalued; if below, it's undervalued.

Historical Valuation

Procept Biorobotics Corp (PRCT) is now in the Undervalued zone, suggesting that its current forward PS ratio of 5.08 is considered Undervalued compared with the five-year average of -27.71. The fair price of Procept Biorobotics Corp (PRCT) is between 45.76 to 134.66 according to relative valuation methord. Compared to the current price of 36.36 USD , Procept Biorobotics Corp is Undervalued By 20.53%.

Relative Value

Fair Zone

45.76-134.66

Current Price：36.36

20.53%

Undervalued

-30.43

-140.05

EV/EBITDA

Procept Biorobotics Corp. (PRCT) has a current EV/EBITDA of -140.05. The 5-year average EV/EBITDA is -52.48. The thresholds are as follows: Strongly Undervalued below -137.65, Undervalued between -137.65 and -95.06, Fairly Valued between -9.90 and -95.06, Overvalued between -9.90 and 32.69, and Strongly Overvalued above 32.69. The current Forward EV/EBITDA of -140.05 falls within the Strongly Undervalued range.

-23.01

EV/EBIT

Procept Biorobotics Corp. (PRCT) has a current EV/EBIT of -23.01. The 5-year average EV/EBIT is -24.27. The thresholds are as follows: Strongly Undervalued below -49.04, Undervalued between -49.04 and -36.65, Fairly Valued between -11.89 and -36.65, Overvalued between -11.89 and 0.50, and Strongly Overvalued above 0.50. The current Forward EV/EBIT of -23.01 falls within the Historic Trend Line -Fairly Valued range.

5.08

Procept Biorobotics Corp. (PRCT) has a current PS of 5.08. The 5-year average PS is 14.36. The thresholds are as follows: Strongly Undervalued below -1.19, Undervalued between -1.19 and 6.58, Fairly Valued between 22.13 and 6.58, Overvalued between 22.13 and 29.90, and Strongly Overvalued above 29.90. The current Forward PS of 5.08 falls within the Undervalued range.

-50.74

P/OCF

Procept Biorobotics Corp. (PRCT) has a current P/OCF of -50.74. The 5-year average P/OCF is -19.56. The thresholds are as follows: Strongly Undervalued below -51.06, Undervalued between -51.06 and -35.31, Fairly Valued between -3.81 and -35.31, Overvalued between -3.81 and 11.94, and Strongly Overvalued above 11.94. The current Forward P/OCF of -50.74 falls within the Undervalued range.

-63.59

P/FCF

Procept Biorobotics Corp. (PRCT) has a current P/FCF of -63.59. The 5-year average P/FCF is -37.25. The thresholds are as follows: Strongly Undervalued below -82.76, Undervalued between -82.76 and -60.00, Fairly Valued between -14.49 and -60.00, Overvalued between -14.49 and 8.26, and Strongly Overvalued above 8.26. The current Forward P/FCF of -63.59 falls within the Undervalued range.

Procept Biorobotics Corp (PRCT) has a current Price-to-Book (P/B) ratio of 5.29. Compared to its 3-year average P/B ratio of 9.83 , the current P/B ratio is approximately -46.21% higher. Relative to its 5-year average P/B ratio of 8.72, the current P/B ratio is about -39.34% higher. Procept Biorobotics Corp (PRCT) has a Forward Free Cash Flow (FCF) yield of approximately -3.96%. Compared to its 3-year average FCF yield of -4.66%, the current FCF yield is approximately -14.94% lower. Relative to its 5-year average FCF yield of -4.50% , the current FCF yield is about -11.85% lower.

5.31

P/B

Median3y

9.83

Median5y

8.72

-3.96

FCF Yield

Median3y

-4.66

Median5y

-4.50

Competitors Valuation Multiple

The average P/S ratio for PRCT's competitors is , providing a benchmark for relative valuation. Procept Biorobotics Corp Corp (PRCT) exhibits a P/S ratio of , which is NaN% above the industry average. Given its robust revenue growth of 42.76%, this premium appears sustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

Revenue Growth

Market Cap

Performance Decomposition

Market capitalization of PRCT decreased by 55.17% over the past 1 year. The primary factor behind the change was an increase in Revenue Growth from 58.37M to 83.33M.

The secondary factor is the Margin Expansion, contributed -28.47%to the performance.

Overall, the performance of PRCT in the past 1 year is driven by Revenue Growth. Which is more sustainable.

42.76%

58.37M → 83.33M

Revenue Growth

-28.47%

-35.93 → -25.70

Margin Expansion

-69.46%

-76.89 → -23.48

P/E Change

-55.17%

80.52 → 36.10

Mkt Cap Growth

People Also Watch

Frequently Asked Questions

Is Procept Biorobotics Corp (PRCT) currently overvalued or undervalued?

What is Procept Biorobotics Corp (PRCT) fair value?

PRCT's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of Procept Biorobotics Corp (PRCT) is between 45.76 to 134.66 according to relative valuation methord.

How does PRCT's valuation metrics compare to the industry average?

What is the current P/B ratio for Procept Biorobotics Corp (PRCT) as of Dec 16 2025?

As of Dec 16 2025, Procept Biorobotics Corp (PRCT) has a P/B ratio of 5.29. This indicates that the market values PRCT at 5.29 times its book value.

What is the current FCF Yield for Procept Biorobotics Corp (PRCT) as of Dec 16 2025?

As of Dec 16 2025, Procept Biorobotics Corp (PRCT) has a FCF Yield of -3.96%. This means that for every dollar of Procept Biorobotics Corp’s market capitalization, the company generates -3.96 cents in free cash flow.

What is the current Forward P/E ratio for Procept Biorobotics Corp (PRCT) as of Dec 16 2025?

As of Dec 16 2025, Procept Biorobotics Corp (PRCT) has a Forward P/E ratio of -30.33. This means the market is willing to pay $-30.33 for every dollar of Procept Biorobotics Corp’s expected earnings over the next 12 months.

What is the current Forward P/S ratio for Procept Biorobotics Corp (PRCT) as of Dec 16 2025?

As of Dec 16 2025, Procept Biorobotics Corp (PRCT) has a Forward P/S ratio of 5.08. This means the market is valuing PRCT at $5.08 for every dollar of expected revenue over the next 12 months.

PRCT Valuation